Cannabidiol (CBD) oil seems to be all over the place, used as treatment for anxiety, chronic pain, acne and even infused in some foods and drinks. It’s readily available in various doses and forms over-the-counter. It’s natural to wonder what this mystical compound of marijuana is and what it does in the body.
Setting yourself up for sleep
Until we have more answers about CBD, there’s a plethora of behavioral strategies that promote better sleep, including:
Allowing yourself time to wind down before bed in a dark setting without bright screens. If you need to look at a screen, make sure you use a brightness filter.
CBD oil is extracted from the marijuana or hemp plant, which are both strains derived from the Cannabis sativa plant.
If you or a loved one is dealing with sleep problems, it's important to see your healthcare provider or a sleep specialist. In some instances, treatment of the underlying problem (e.g., an overactive thyroid or changing a medication) will resolve the problem. Other diagnoses may require a more comprehensive approach.
Hemp-derived CBD is legal in all 50 states. However, state laws vary with regard to the legality of marijuana. CBD oil that still contains THC or other cannabinoids may only be sold in states that have legalized marijuana use.
Research suggests that, in the short-term, CBD is largely safe and well-tolerated. Some people, however, do experience side effects, such as:
Arno Kroner, DAOM, LAc, is a board-certified acupuncturist, herbalist, and integrative medicine doctor practicing in Santa Monica, California.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Cannabinoids, including the two main phytocannabinoids Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), are being increasingly utilised as pharmacological interventions for sleep disorders. THC and CBD are known to interact with the endocannabinoid and other neurochemical systems to influence anxiety, mood, autonomic function, and circadian sleep/wake cycle. However, their therapeutic efficacy and safety as treatments for sleep disorders are unclear. The current systematic review assessed the available evidence base using PubMed, Scopus, Web of Science, Embase, CINAHL and PsycInfo databases. A total of 14 preclinical studies and 12 clinical studies met inclusion criteria. Results indicated that there is insufficient evidence to support routine clinical use of cannabinoid therapies for the treatment of any sleep disorder given the lack of published research and the moderate-to-high risk of bias identified within the majority of preclinical and clinical studies completed to-date. Promising preliminary evidence provides the rationale for future randomised controlled trials of cannabinoid therapies in individuals with sleep apnea, insomnia, post-traumatic stress disorder-related nightmares, restless legs syndrome, rapid eye movement sleep behaviour disorder, and narcolepsy. There is a clear need for further investigations on the safety and efficacy of cannabinoid therapies for treating sleep disorders using larger, rigorously controlled, longer-term trials.
Keywords: Cannabidiol; Cannabinoids; Cannabis; Insomnia; Obstructive sleep apnea; Sleep disorders; THC.
Conflicts of interest RRG and NSM have received discounted investigational products for an unrelated clinical trial from Neurim Pharmaceuticals Inc. RRG and NSM have also received investigational product and matched placebo from Teva Pharmaceutical in unrelated clinical trials. ISM is a consultant for Kinoxis Therapeutics, and is an inventor on several patents relating to novel cannabinoid therapeutics. RV has received income as a consultant or advisory board member from Zynerba Pharmaceuticals, Canopy Health Innovations Inc., and FSD Pharma. The other authors have no conflicts of interest to disclose.